Our Journey
Take a look at our journey of creating the first comprehensive AI diagnostic solutions.
Mediwhale’s Most Defining Moments
2024
December
Obtained ISO27001 Certification
Won CB Insight Digital Health 50 – Non-Invasive diagnostics
November
Presented 3 abstracts at American Heart Association 2024 Annual conference
October
Presented the research results at the American Society of Nephrology(ASN)
Awarded 1st place in the diabetic retinopathy and diabetic macular edema Analysis Challenge(MMAC) hosted by The Medical Image Computing and Computer Assisted Intervention(MICCAI)
CMO, Tyler Rim, selected as one of the top 2% scientists worldwide
September
Press Conference – The future of digital healthcare through Dr. Noon
Raised $12 milion in Series A2 Funding
July
First prescription at Cardiology department of Severance hospital
June
May
Published review article of Dr. Noon CVD in Eye and Vision, a journal of Springer Nature
Presented abstracts of Dr. Noon CVD at ARVO 2024
Presented abstract of Dr. Noon CKD at ERA 2024
January
Dr. Noon CKD clinical trial protocol approval by Korean Ministry of Food and Drug Administration
2023
December
Obtained New Excellent Technology (NET) designated by the Ministry of Health and Welfare
November
Secured 1st place at the ‘E-nnova Health 2023 Awards’ in Spain
Presented the research results at the American Heart Association (AHA) and American Society of Nephrology(ASN)
October
CMO, Tyler Rim, selected as one of the top 2% scientists worldwide
September
Awarded 3rd place in the Myoptic Maculopathy Analysis Challenge(MMAC) hosted by The Medical Image Computing and Computer Assisted Intervention(MICCAI)
August
Presented the research results at the 2023 European Society of Cardiology (ESC) conference
Reti-CKD was designated as the Innovative Medical Device by the Ministry of Food and Drug Safety of Korea
June
Emerged as the winner of the ‘CKD Challenge’ organized by AstraZeneca with the collaboration of Wayra
Proof of concept paper for Dr. Noon CKD was published in the npj Digital Medicine(IF 15.357), a portfolio journal of the Nature
Physicians can charge patients for Dr. Noon CVD for diagnosis and treatment purposes as it was selected for the Postponement of New Health Technology Assessment (nHTA)
March
Raises $9 million Series A round for AI-empowered eye scans predicting future diseases
Joined the MedTech Accelerator program at Mayo Clinic and Arizona State University
January
Joined StartX, a prestigious Silicon Valley-based accelerator program affiliated with Stanford University and Stanford Healthcare
2022
November
Awarded CES Innovation Award 2023 for Reti-CVD
Presented at the American Heart Association (AHA) Scientific Session in Chicago and the American Society of Nephrology’s (ASN) Kidney Week in Orlando, Florida
Dr. Noon CVD was confirmed to be the candidate of the New Health Technology Assessment (nHTA) by the HIRA (Health Insurance Review and Assessment Service) in Korea, meaning it is a new medical practice that requires separate compensation by the Korean national insurance
October
Selected in HeartX 2022, a cardiovascular-focused healthcare accelerator program supported by HealthTech Arkansas and MedAxiom
Joined Innovator’s Network of Center for Health Technology & Innovation at the American Heart Association
Dr. Noon Fundus & Dr. Noon CVD were registered as medical devices by Food and Drug Administration of Thailand – Category : Cardiovascular risk assessment based on retinal image & eye screening service
August
Dr. Noon CVD was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea
June
Dr. Noon Fundus was installed in Cheonho public health clinic in Seoul as part of a metabolic disease prevention campaign
April
“Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk” was published in the peer-reviewed medical journal, Age and Ageing (IF:12.8)
Dr. Noon Fundus & Dr. Noon CVD were registered as class IIa medical devices by the National Agency of Drug and Food Control (NA-DFC) of Indonesia – Category: Cardiovascular risk assessment based on retinal image & eye screening service
February
Singapore office was opened
Dr. Noon Fundus & Dr. Noon CVD were registered as class B medical devices by Health Sciences Authority (HSA) of Singapore – Category: Cardiovascular risk assessment based on retinal image & eye screening service
Dr. Noon Fundus & Dr. Noon CVD were registered as a medical device by Medicines and Healthcare products Regulatory Agency of UK – Category: Cardiovascular risk assessment based on retinal image & eye screening service
2021
December
Dr. Noon Fundus & Dr. Noon CVD were registered as a class IIa medical device by the Australian Registry of Therapeutic Goods (ARTG)
October
Dr. Noon Fundus & Dr. Noon CVD were registered as class B medical devices by the Ministry of Health of Malaysia
August
Raised $2 mil Pre-A round from Korean investors led by SBI Investment
A patent “AI technology that predicts cardiovascular disease risk through retinal image” was transferred from Singapore Eye Center
May
Dr. Noon Fundus & Dr. Noon CVD obtained CE approval as a class IIa medical device in the EU – Category: Cardiovascular risk assessment based on retinal image & eye screening service
“Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs” was published in a top-tier medical journal (The Lancet Digital Health, IF:36.6)
2020
December
Dr. Noon CVD was registered as an innovative medical device by the Ministry of Food and Drug Safety of Korea for screening cardiovascular risk
November
“Prediction of systemic biomarkers from retinal photographs: development and validation of deep-learning algorithms” was published in a top-tier medical journal (The Lancet Digital Health, IF: 36.6)
August
Dr. Noon Fundus was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea
May
ISO 13485 certification was obtained
2019
July
A research collaboration agreement was signed with Singapore Eye Research Institute (SERI)
March
KGMP (Korean Good Manufacturing Practice) certificate was obtained
February
8 patented technologies were transferred from Yonsei University including “Retinal image analysis method” and “Cardiovascular disease diagnosis through retinal image”
2018
August
A research collaboration agreement was signed with Yonsei University Health System to develop AI-based eye screening technology through retinal image analysis
March
“Retinal image analysis method” technologies were transferred from Yonsei University
2017
September
A leadership team of Kevin Taegeun Choi, Tyler Hyungtaek Rim, and Young Geunyoung Lee was formed
MARCH
2nd place was awarded in the biggest medical data analysis competition hosted by Asan Medical Center & Microsoft Korea
2016
December
Mediwhale Inc. was founded in Seoul, Korea